Form 4: Edgewise Therapeutics Grants Executive Equity Awards

Edgewise Therapeutics, Inc. disclosed new equity grants to its Chief Development Officer, Robert Blaustein, including restricted stock units and stock options.

Summary

• Robert Blaustein, Chief Development Officer of Edgewise Therapeutics, Inc. (EWTX), was granted 17,500 Restricted Stock Units (RSUs) on August 12, 2025.
• These RSUs will vest in four equal annual installments, commencing on August 12, 2026.
• Additionally, Mr. Blaustein received 105,000 stock options with an exercise price of $13.39 per share on August 12, 2025.
• The stock options will vest monthly at a rate of 1/48th of the total shares, beginning on September 12, 2025, contingent on his continued service.
• Both the RSUs and stock options have an expiration date of August 12, 2035.

Sentiment

Score: 6

Explanation: The filing discloses standard executive compensation, which is a neutral to slightly positive event as it aids in executive retention and aligns interests with shareholders.

Positives

• The equity grants serve as a form of executive compensation, aligning the Chief Development Officer's interests with long-term shareholder value.
• The vesting schedules for both RSUs and stock options are designed to incentivize long-term retention and performance of a key executive.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of executive compensation in the biotechnology or pharmaceutical industry, where equity grants are a common component of remuneration packages designed to attract and retain key talent.

Stakeholder Impact

• Shareholders: Potential minor dilution from the issuance of new shares upon vesting and exercise, but also benefit from incentivized executive performance and retention.
• Employees: May view this as a positive sign of executive commitment and a standard practice for compensation.

Next Steps

• Vesting of 1/48th of stock options each month beginning September 12, 2025.
• Vesting of 1/4th of Restricted Stock Units annually beginning August 12, 2026.

Key Dates

Keywords

Edgewise Therapeutics, EWTX, SEC Form 4, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Insider Transaction, Equity Grant, Chief Development Officer